RxDoctor Payments Data

Thomas Smith

Critical Care Medicine · Albany, NYNPI 1134115306

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,148 of the $3,290 with a category attached, or 65.3%. AstraZeneca accounts for 79.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,527 and has fallen 99.3% since, to $17 in 2025.

$3,290in general payments, 2019–2025

Across 19 payments — averaging $173.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$488
  • Chiesi USA, Inc.$138
  • Pfizer$33
  • Sanofi Pasteur Inc.$17
$533,314in research payments, 2019–2025

Across 18 payments — averaging $29,629 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$533K
  • Vivus LLC$324

What the payments were for

  • Consulting fees$2,14865%
  • Food & beverage$1,12834%
  • Education$140%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca6$2,614
GSK6$488
Chiesi USA, Inc.4$138
Pfizer2$33
Sanofi Pasteur Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,290 in reported general payments places this provider in the 85th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Other critical care medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →